Evidence map›Paper›PMID 31595795›Full record

ArticleIntegrative cancer therapies

The Possible Role of PD-1 Protein in

Gan Wang, Le Wang, Jianlong Zhou, Xiaoxin Xu

Open access · goldAbstract read
In one paragraph

Article in Integrative cancer therapies. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Effects ofFrontiers in nutrition · 2023
    Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Gan WangWayne State University, Detroit, MI, USA.ORCID 0000-0002-4981-8845
Le WangWayne State University, Detroit, MI, USA.
Jianlong ZhouLongevity Valley Pharmaceuticals Co Ltd, Wuyi, Zhejiang Province, People's Republic of China.
Xiaoxin XuLutuo Pharmaceuticals Inc, Jinan, Shandong Province, People's Republic of China.
Wayne State University · USLuye Pharma (China) · CN

Funding

Tumor Biology and Microenvironment (Program 1)P30CA022453 · NCI · WAYNE STATE UNIVERSITY · PI PAUL M STEMMER · 1985 to 2026
$68.4M
Pilot Project ProgramP30ES020957 · NIEHS · WAYNE STATE UNIVERSITY · PI RUNGE-MORRIS, MELISSA A · 2014 to 2021
$10.1M
NCI NIH HHS P30 CA022453NIEHS NIH HHS P30 ES020957
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Biological ProductsCell Line, TumorChemokine CCL5HumansImmunomodulationMedicine, Chinese TraditionalNeoplasmsProgrammed Cell Death 1 ReceptorReishiTransduction, GeneticBiological ProductsChemokine CCL5PDCD1 protein, humanProgrammed Cell Death 1 ReceptorB-lymphocytesGanoderma lucidumGanoderma lucidum spore extractGLEimmunomodulationnovel immunomodulatorsPD-1protein reductiontranscription inhibition

Identifiers

PMID31595795
PMCPMC6876169
OpenAlexW2980008054

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.